HIMS vs. LLY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at HIMS and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
LLY’s market capitalization of 734.92 billion USD is significantly greater than HIMS’s 10.65 billion USD, highlighting its more substantial market valuation.
HIMS’s beta of 2.10 points to significantly higher volatility compared to LLY (beta: 0.39), suggesting HIMS has greater potential for both gains and losses relative to market movements.
| Symbol | HIMS | LLY |
|---|---|---|
| Company Name | Hims & Hers Health, Inc. | Eli Lilly and Company |
| Country | US | US |
| Sector | Consumer Defensive | Healthcare |
| Industry | Household & Personal Products | Drug Manufacturers - General |
| CEO | Andrew Dudum | David A. Ricks |
| Price | 49.41 USD | 775.45 USD |
| Market Cap | 10.65 billion USD | 734.92 billion USD |
| Beta | 2.10 | 0.39 |
| Exchange | NYSE | NYSE |
| IPO Date | September 13, 2019 | June 1, 1972 |
| ADR | No | No |
Historical Performance
This chart compares the performance of HIMS and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
HIMS
35.97%
Household & Personal Products Industry
- Max
- 35.97%
- Q3
- 34.73%
- Median
- 27.11%
- Q1
- 12.31%
- Min
- -18.42%
In the upper quartile for the Household & Personal Products industry, HIMS’s Return on Equity of 35.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
LLY
76.92%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 78.00%
- Median
- 31.21%
- Q1
- 16.63%
- Min
- 2.76%
LLY’s Return on Equity of 76.92% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
HIMS
24.52%
Household & Personal Products Industry
- Max
- 34.47%
- Q3
- 23.36%
- Median
- 13.65%
- Q1
- 4.92%
- Min
- -4.23%
In the upper quartile for the Household & Personal Products industry, HIMS’s Return on Invested Capital of 24.52% signifies a highly effective use of its capital to generate profits when compared to its peers.
LLY
25.72%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
In the upper quartile for the Drug Manufacturers - General industry, LLY’s Return on Invested Capital of 25.72% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
HIMS
9.21%
Household & Personal Products Industry
- Max
- 18.46%
- Q3
- 13.34%
- Median
- 9.48%
- Q1
- 5.58%
- Min
- -5.89%
HIMS’s Net Profit Margin of 9.21% is aligned with the median group of its peers in the Household & Personal Products industry. This indicates its ability to convert revenue into profit is typical for the sector.
LLY
22.66%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
LLY’s Net Profit Margin of 22.66% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
HIMS
6.16%
Household & Personal Products Industry
- Max
- 23.81%
- Q3
- 17.91%
- Median
- 14.30%
- Q1
- 7.03%
- Min
- -4.25%
HIMS’s Operating Profit Margin of 6.16% is in the lower quartile for the Household & Personal Products industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
LLY
40.70%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
An Operating Profit Margin of 40.70% places LLY in the upper quartile for the Drug Manufacturers - General industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | HIMS | LLY |
|---|---|---|
| Return on Equity (TTM) | 35.97% | 76.92% |
| Return on Assets (TTM) | 18.44% | 12.42% |
| Return on Invested Capital (TTM) | 24.52% | 25.72% |
| Net Profit Margin (TTM) | 9.21% | 22.66% |
| Operating Profit Margin (TTM) | 6.16% | 40.70% |
| Gross Profit Margin (TTM) | 77.04% | 81.70% |
Financial Strength
Current Ratio
HIMS
1.59
Household & Personal Products Industry
- Max
- 1.95
- Q3
- 1.55
- Median
- 0.85
- Q1
- 0.78
- Min
- 0.71
HIMS’s Current Ratio of 1.59 is in the upper quartile for the Household & Personal Products industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
LLY
1.37
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.38
- Median
- 1.27
- Q1
- 0.89
- Min
- 0.74
LLY’s Current Ratio of 1.37 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
HIMS
0.12
Household & Personal Products Industry
- Max
- 2.16
- Q3
- 2.16
- Median
- 1.12
- Q1
- 0.65
- Min
- 0.09
Falling into the lower quartile for the Household & Personal Products industry, HIMS’s Debt-to-Equity Ratio of 0.12 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
LLY
2.44
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.57
- Median
- 1.08
- Q1
- 0.71
- Min
- 0.28
LLY’s Debt-to-Equity Ratio of 2.44 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
HIMS
--
Household & Personal Products Industry
- Max
- 33.09
- Q3
- 14.63
- Median
- 8.70
- Q1
- 0.93
- Min
- -1.74
Interest Coverage Ratio data for HIMS is currently unavailable.
LLY
23.61
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
LLY’s Interest Coverage Ratio of 23.61 is in the upper quartile for the Drug Manufacturers - General industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | HIMS | LLY |
|---|---|---|
| Current Ratio (TTM) | 1.59 | 1.37 |
| Quick Ratio (TTM) | 1.32 | 1.06 |
| Debt-to-Equity Ratio (TTM) | 0.12 | 2.44 |
| Debt-to-Asset Ratio (TTM) | 0.07 | 0.43 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.59 | 2.18 |
| Interest Coverage Ratio (TTM) | -- | 23.61 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for HIMS and LLY. These metrics are based on the companies’ annual financial reports.
Revenue Growth (YoY)
EPS Growth (YoY)
Free Cash Flow Growth (YoY)
Dividend
Dividend Yield
HIMS
0.00%
Household & Personal Products Industry
- Max
- 5.15%
- Q3
- 3.67%
- Median
- 2.31%
- Q1
- 0.64%
- Min
- 0.00%
HIMS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
LLY
0.72%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.27%
- Median
- 3.42%
- Q1
- 2.43%
- Min
- 0.00%
LLY’s Dividend Yield of 0.72% is in the lower quartile for the Drug Manufacturers - General industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio
HIMS
0.00%
Household & Personal Products Industry
- Max
- 147.82%
- Q3
- 70.76%
- Median
- 62.17%
- Q1
- 34.13%
- Min
- 0.00%
HIMS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
LLY
43.74%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 79.84%
- Median
- 61.93%
- Q1
- 45.09%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 43.74% is in the lower quartile for the Drug Manufacturers - General industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.
Dividend at a Glance
| Symbol | HIMS | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.72% |
| Dividend Payout Ratio (TTM) | 0.00% | 43.74% |
Valuation
Price-to-Earnings Ratio
HIMS
66.72
Household & Personal Products Industry
- Max
- 66.72
- Q3
- 40.51
- Median
- 25.04
- Q1
- 21.85
- Min
- 17.21
A P/E Ratio of 66.72 places HIMS in the upper quartile for the Household & Personal Products industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
LLY
62.75
Drug Manufacturers - General Industry
- Max
- 27.97
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
At 62.75, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
HIMS
1.80
Household & Personal Products Industry
- Max
- 5.42
- Q3
- 4.43
- Median
- 3.18
- Q1
- 2.52
- Min
- 1.80
In the lower quartile for the Household & Personal Products industry, HIMS’s Forward PEG Ratio of 1.80 is a positive indicator. It suggests that the stock may be attractively valued relative to its expected earnings growth.
LLY
2.79
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
LLY’s Forward PEG Ratio of 2.79 is within the middle range of its peers in the Drug Manufacturers - General industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
HIMS
5.97
Household & Personal Products Industry
- Max
- 5.97
- Q3
- 3.78
- Median
- 2.63
- Q1
- 2.09
- Min
- 0.30
HIMS’s P/S Ratio of 5.97 is in the upper echelon for the Household & Personal Products industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
LLY
15.00
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
With a P/S Ratio of 15.00, LLY trades at a valuation that eclipses even the highest in the Drug Manufacturers - General industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
HIMS
19.97
Household & Personal Products Industry
- Max
- 38.54
- Q3
- 19.97
- Median
- 6.64
- Q1
- 4.80
- Min
- 0.84
HIMS’s P/B Ratio of 19.97 is within the conventional range for the Household & Personal Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
LLY
44.21
Drug Manufacturers - General Industry
- Max
- 14.02
- Q3
- 8.90
- Median
- 5.00
- Q1
- 3.42
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | HIMS | LLY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 66.72 | 62.75 |
| Forward PEG Ratio (TTM) | 1.80 | 2.79 |
| Price-to-Sales Ratio (P/S, TTM) | 5.97 | 15.00 |
| Price-to-Book Ratio (P/B, TTM) | 19.97 | 44.21 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 44.32 | 1508.46 |
| EV-to-EBITDA (TTM) | 78.90 | 47.34 |
| EV-to-Sales (TTM) | 5.85 | 15.72 |